Nicholas Kenyon, MD
Critical Care Medicine · Sacramento, CANPI 1689657512
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Regeneron Healthcare Solutions, Inc. accounts for 62.7% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $4,822 and has fallen 94.9% since, to $244 in 2025.
Across 42 payments — averaging $145.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$4K
- Astrazeneca UK Limited$1K
- AstraZeneca$321
- GSK$162
- Genentech USA, Inc.$145
- Sanofi$131
- plus $308 from 6 others
Across 2 payments — averaging $11,693 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$15K
- AstraZeneca$8K
What the payments were for
- Consulting fees$3,34055%
- Travel & lodging$95316%
- Food & beverage$1,81430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 10 | $3,832 |
| Astrazeneca UK Limited | 8 | $1,207 |
| AstraZeneca | 4 | $321 |
| GSK | 4 | $162 |
| Genentech USA, Inc. | 1 | $145 |
| Sanofi | 2 | $131 |
| Mylan Specialty L.p. | 1 | $113 |
| Electromed, Inc. | 7 | $81 |
| Sunovion Pharmaceuticals Inc. | 2 | $35 |
| Genentech, Inc. | 1 | $32 |
| Novartis | 1 | $28 |
| Regeneron | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,107 in reported general payments places this provider in the 85th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 64 | $234,454 |
| TezspireTezepelumab-Ekko | 51 | $217,448 |
| Fasenra PenBenralizumab | 19 | $105,885 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $21,729 |
| Spiriva RespimatTiotropium Bromide | 27 | $18,824 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $14,511 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $11,192 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,101 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $3,269 |
| Wixela InhubFluticasone Propion/Salmeterol | 26 | $2,963 |
| Fluticasone Propionate HfaFluticasone Propionate | 11 | $2,688 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,237 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $2,123 |
| Epinephrine | 11 | $2,012 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $1,547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Symbicort | $321 | $228,64078 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta, Arnuity Ellipta | $162 | $42,57984 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 715 critical care medicine providers in California.
Other critical care medicine in Sacramento
- Chinh PhanSacramento$467K
- Timothy AlbertsonSacramento$418K
- Ken YonedaSacramento$173K
- Muhammad AfzalSacramento$72K
- Cedric Franklin RutlandRiverside$3.2M
- Stephen ChenMonterey Park$394K
- Bassam YaghmourOrange$376K
- Xuanha WhiteSan Diego$343K
- Praveen AkuthotaSan Diego$169K
- Ivan ChengSan Francisco$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.